Jon has been reporting on stock markets for over twenty-five years for audio text companies (remember them?!), newswires, and websites. He helped set up MarketEye News for ICV/Topic in the 1990’s before moving on to become a Markets reporter at AFX News. After over 10 years, which saw him rise to the dizzy heights of Markets Editor at AFX, the firm’s acquisition by Thomson Corp and subsequent takeover of Reuters, he moved on in 2012. Prior to Proactive Investors, he was News Editor for thisismoney.co.uk, the Mail Online’s financial website.
Celegene said the FDA's decision was due to risks seen in other trials for another checkpoint inhibitor, Merck & Co.'s anti-PD-1 antibody pembrolizumab, in combination with immunomodulatory agents
Mike van Dulken, head of research at Accendo Markets said the share price reaction “may in fact be due to a downgraded Risk & Uncertainties statement, buried half way through the report before the financial statements"
The Natixis analysts said: “We expect successful results for MYSTIC, which prompts our target of 5,738p, up from 5,000p previously, but still giving over 25% upside potential”
The FTSE 250-listed firm pointed out that average selling prices exceeded £273,000 per unit for the first time in the group's history, up from £264,000 in 2016.
The FTSE 250-listed global healthcare specialist said a court in Delaware had issued the ruling in a case concerning the commercialisation of Vistogard, finding that the British company had breached the distribution agreement
The AIM-listed biotechnology company said the funds raised will be used for “advancing the clinical dose escalation of VAL201 and for further progressing the late pre-clinical development of GeneICE and general working capital purposes”
The once-a-day triple inhaler combines the drugs fluticasone furoate, umeclidinium and vilanterol and will have a proposed brand name of Trelegy Ellipta
The transatlantic healthcare IP commercialisation group said the appointment is expected to accelerate the commercial uptake of ProAxsis' technology, increasing near-term sales potential